Compare J B Hunt Transport Services Inc (JBHT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Sanofi SA — how do they compare? J B Hunt Transport Services Inc trades at $229.9 (market cap $21.45B), while Sanofi SA trades at $40.14 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 4.4× J B Hunt Transport Services Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold J B Hunt Transport Services Inc for 46 Days and Sanofi SA for 94 Days on average.
| JBHT | SNY | |
|---|---|---|
Market Cap | $21.45B | $95.18B |
Volume | 1,028,680 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $298.41 | $52.34 |
52-Week Low | $137.09 | $39.51 |
Typical Hold Time | 46 Days | 94 Days |
Enterprise Value | $22.59B | $114.48B |
Dividend Yield | 0.79% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $228.91, up 2.82% today, with a bearish technical signal and neutral oscillators. The company reported revenue of $12.00B in 2025, with net income of $598.28M and a net margin of 5.31%. Recent earnings have consistently beaten estimates, but the stock faces headwinds from rising costs and multiple securities class action investigations announced in late September 2026.
The outlook is mixed: strong analyst consensus with a $289.40 price target suggests upside, but near-term risks from cost pressures and legal scrutiny cloud the picture. Earnings growth and freight demand remain key drivers, yet investor sentiment is cautious amid profit warnings and volatile diesel prices.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
